| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 4,890 | 4,710 | 3,250 | 1,010 | 80 |
| Sales Growth | +3.82% | +44.92% | +221.78% | +1,162.50% | unch |
| Net Income | -64,100 | -46,770 | -32,900 | -32,680 | -13,990 |
| Net Income Growth | -37.05% | -42.16% | -0.67% | -133.60% | unch |
Nyxoah S A (NYXH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Nyxoah SA is a medical technology company. It focused on the development and commercialization of solutions to treat Obstructive Sleep Apnea. Nyxoah SA is based in Belgium.
Fiscal Year End Date: 12/31